Ikena Oncology (NASDAQ:IKNA - Get Free Report)'s stock had its "neutral" rating reaffirmed by investment analysts at Wedbush in a research report issued to clients and investors on Monday,RTT News reports. They presently have a $2.00 price objective on the stock. Wedbush's price target points to a potential upside of 19.76% from the company's current price.
Separately, HC Wainwright reiterated a "buy" rating and issued a $4.00 price target on shares of Ikena Oncology in a research note on Monday, November 11th.
Check Out Our Latest Analysis on Ikena Oncology
Ikena Oncology Stock Performance
IKNA traded up $0.12 during trading on Monday, hitting $1.67. 5,144,815 shares of the stock were exchanged, compared to its average volume of 250,165. The firm has a 50 day simple moving average of $1.69 and a 200 day simple moving average of $1.69. The firm has a market cap of $80.59 million, a price-to-earnings ratio of -1.36 and a beta of 0.49. Ikena Oncology has a 1 year low of $1.22 and a 1 year high of $2.29.
Ikena Oncology (NASDAQ:IKNA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.08. As a group, equities analysts anticipate that Ikena Oncology will post -0.91 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Ikena Oncology
A number of hedge funds have recently made changes to their positions in IKNA. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Ikena Oncology in the second quarter worth about $30,000. BBR Partners LLC acquired a new stake in Ikena Oncology in the 2nd quarter valued at about $33,000. AQR Capital Management LLC purchased a new position in Ikena Oncology in the 2nd quarter worth approximately $36,000. FMR LLC boosted its holdings in shares of Ikena Oncology by 94.1% during the 3rd quarter. FMR LLC now owns 38,374 shares of the company's stock worth $66,000 after purchasing an additional 18,607 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ikena Oncology in the second quarter valued at approximately $75,000. Institutional investors and hedge funds own 75.00% of the company's stock.
About Ikena Oncology
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
